Pembrolizumab + Chemotherapy For First-Line Treatment Of Patients With Persistent, Recurrent, Or Metastatic Cervical Cancer: Bevacizumab Subgroup Analysis Based On Protocol-Specified Final Overall Survival Results Of KEYNOTE-826

Magnetic Resonance Imaging Or Expert Ultrasound In Preoperative Local Staging Of Patients With Early-Stage Cervical Cancer: Final Results Of The SENTIX Prospective, Single-Arm, International Trial (CEEGOG CX-01; ENGOT-CX2)

Long-Term Follow Up Of Selinexor Maintenance For Patients With TP53wt Advanced Or Recurrent Endometrial Cancer: A Pre-Specified Subgroup Analysis From The Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study

Quality-Adjusted Time Without Symptoms Of Disease Or Toxicity In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel In The ENGOT-EN6/GOG-3031/RUBY Trial

DB-1303, A HER2-Targeting ADC, For Patients With Advanced/Metastatic Endometrial Cancer: Preliminary Clinical Results From An Ongoing Phase 1/2a Trial (NCT05150691)

Safety Of Dostarlimab In Combination With Chemotherapy In Patients With Primary Advanced Or Recurrent Endometrial Cancer In A Phase 3, Randomized, Placebo-Controlled Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Near-Infrared FluORescencE Assessment Of Myocutnaeous Flap Microperfusion For Gynecologic RecONstrucTion (FOREFRONT): A Prospective, Non-Randomized Trial (NCT05071976)

Initial Efficacy And Safety Results From ENGOT-Ov60/GOG-3052/RAMP 201: A Phase 2 Study Of Avutometinib (VS-6766) ± Defactinib In Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Efficacy Of Subsequent Chemotherapy Followed By PARP Inhibitor Maintenance In Patients With Advanced Ovarian Cancer In The Phase III PAOLA-1/ENGOT-Ov25 Trial

First Experience With Intra-Abdominal 224Radium-Labelled Microparticles (Radspherin) After Cytoreductive Surgery For Peritoneal Metastasis In Recurrent Epithelial Ovarian Cancer (Phase 1 Study)

Niraparib Maintenance Therapy In Patients Aged 75 Years And Older With Platinum-Sensitive Recurrent Ovarian Cancer: A Subgroup Assessment Of The GEICO-88R Study

Results From A Phase I/II Trial Of Tinostamustine Monotherapy In Advanced Solid Tumours (NCT03345485): Safety And Efficacy In A Subset Of Patients With Advanced Ovarian Cancer (OvCa)

PARP-Inhibitors Can Be Applied Together With Tumor Treating Fields (TTFields) To Prolong Survival In An Ovarian Cancer Mouse Model

Hyperthermic Intraperitoneal Chemotherapy In Platinum-Sensitive Relapsed Epithelial Ovarian Cancer: The CHIPOR Randomised Phase III Trial.

Real-World Treatment, Clinical And Patient-Reported Outcomes In Patients With Newly Diagnosed Advanced Ovarian Cancer: Up-Date On The Cumulative Numbers Of Patients Treated At The Sites (NOGGO Ov54, NCT04830709)